Loading provider…
Loading provider…
Ophthalmology Physician in Rochester, MN
NPI: 1326263963Primary Practice Location
MAYO CLINIC HOSPITAL ROCHESTER
201 W Center St, Rochester, MN
Primary Employer
Mayo Clinic - Mayo Building and Gonda Building
mayoclinic.org
HQ Phone
Get M.D. Wendy's Phone Numberphone_androidMobile
Get M.D. Wendy's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOH State Medical License
MN State Medical License
MN State Medical License
2012 - 2026
OH State Medical License
2006 - 2014

American Board of Ophthalmology
Ophthalmology
National Institutes of Health Clinical Center
Fellowship • Ocular Immunology/Uveitis
2010 - 2012
Ohio State College of Medicine
medicine.osu.edu
Medical School
Until 2006
Ohio State University Hospital
Residency • Ophthalmology
2007 - 2010
Internship • Internal Medicine
2006 - 2007
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 67028Injection of drug into eye | 460 | 1,008 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 155 | 291 |
| 3 | 92134Diagnostic imaging of retina | 153 | 294 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 24 | 27 |
| 5 | 92133Diagnostic imaging of optic nerve of eye | 20 | 22 |
Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study
Authors: Rodrigo Cartin-Ceba
Publication Date: 2017-10
Epidemiology of Uveitis in Olmsted County, Minnesota: A Population-Based Follow-Up Study.
The eye and tick-borne disease in the United States.
Authors: Saraniya Sathiamoorthi
Journal: Curr Opin Ophthalmol
Lead Sponsor: JHSPH Center for Clinical Trials
Intervention / Treatment: BIOLOGICAL: Adalimumab (ADA), DRUG: Conventional immunosuppression (CON)
Lead Sponsor: JHSPH Center for Clinical Trials
Collaborators: National Eye Institute (NEI)
Intervention / Treatment: DRUG: Dexamethasone intravitreal implant 0.7 mg, DRUG: Intravitreal Methotrexate 400 µg, DRUG: Intravitreal Ranibizumab 0.5 mg
Lead Sponsor: JHSPH Center for Clinical Trials
Collaborators: National Eye Institute (NEI)
Intervention / Treatment: DRUG: Periocular triamcinolone 40 mg, DRUG: Intravitreal triamcinolone 4 mg, DRUG: Dexamethasone intravitreal implant